{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:18:04Z","timestamp":1760347084224,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The treatment strategy for metastatic lesions of primary malignant melanoma of the esophagus (PMME) is currently determined on a case-by-case basis, based on the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma. The NCCN guidelines state that resection should be considered in patients with resectable metastatic recurrence. Herein, we report a case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for the metastatic recurrence of PMME.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 65-year-old female patient with PMME underwent thoracoscopic subtotal esophagectomy, gastric tube reconstruction via the posterior mediastinal route, and cervical esophagogastric anastomosis. Histopathological examination of the resected specimen revealed that the tumor was PMME with tumor invasion into the muscularis propria and no lymph node metastasis. At the age of 68\u00a0years, she developed intestinal invagination due to jejunal metastasis of malignant melanoma and underwent resection of the jejunum. Histopathological examination of the resected specimen revealed two metastases of malignant melanoma in the jejunum and one metastasis to the mesenteric lymph node. At the age of 75\u00a0years, a recurrence of malignant melanoma was found in the cervical esophagus. She underwent thoracoscopic mobilization of the gastric tube and esophagus followed by cervical esophagectomy and reconstruction with a free jejunum flap. She received 24 courses of nivolumab therapy for 1\u00a0year as a postoperative adjuvant therapy. Subsequently, at the age of 78\u00a0years, an enlarged left cervical lymph node and a mass in the right lower lobe of the lung were found. She underwent left cervical lymph node dissection and thoracoscopic wedge resection of the right lung. Histopathological examination of the resected specimens revealed that both tumors were metastases of malignant melanoma. At age 79\u00a0years, she received eight courses of nivolumab therapy as a second postoperative adjuvant therapy, with no sign of recurrence in a 9-month follow-up period after the third metastasectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In cases of metastatic recurrence of PMME, aggressive resection of oligometastasis with postoperative adjuvant nivolumab therapy may result in long-term survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-022-01561-z","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T20:19:11Z","timestamp":1667593151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus"],"prefix":"10.1186","volume":"8","author":[{"given":"Keita","family":"Hanada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-7352","authenticated-orcid":false,"given":"Shigeru","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yojiro","family":"Yutaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuto","family":"Nishigori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Hisamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisatsugu","family":"Maekewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Itami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Obama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"1561_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/1759-7714.13034","volume":"10","author":"X Wang","year":"2019","unstructured":"Wang X, Kong Y, Chi Z, Sheng X, Cui C, Mao L, et al. Primary malignant melanoma of the esophagus: a retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer. 2019;10:950\u20136.","journal-title":"Thorac Cancer"},{"key":"1561_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10388-015-0484-6","volume":"12","author":"H Makuuchi","year":"2015","unstructured":"Makuuchi H, Takubo K, Yanagisawa A, Yamamoto S. Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society. Esophagus. 2015;12:158\u201369.","journal-title":"Esophagus"},{"key":"1561_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtcvs.2020.03.006","volume":"161","author":"L Dai","year":"2021","unstructured":"Dai L, Wang ZM, Xue ZQ, He M, Yuan Y, Shang XQ, et al. Results of surgical treatment for primary malignant melanoma of the esophagus: a multicenter retrospective study. J Thorac Cardiovasc Surg. 2021;161:294\u2013302.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1561_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"key":"1561_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:367\u2013402.","journal-title":"J Natl Compr Canc Netw"},{"key":"1561_CR6","first-page":"528","volume":"8","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Uchikado Y, Omoto I, Amatatsu M, Megumi K, Okumura H, et al. Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: a case report. Mol Clin Oncol. 2018;8:528\u201332.","journal-title":"Mol Clin Oncol"},{"key":"1561_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijscr.2020.09.034","volume":"75","author":"F Endo","year":"2020","unstructured":"Endo F, Akiyama Y, Onishi M, Fujisawa R, Sasaki N, Nikai H, et al. Primary esophageal malignant melanoma successfully treated with anti-PD-1 antibody for retroperitoneal recurrence after esophagectomy: a case report. Int J Surg Case Rep. 2020;75:152\u20136.","journal-title":"Int J Surg Case Rep"},{"key":"1561_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13256-021-02821-6","volume":"15","author":"S Ito","year":"2021","unstructured":"Ito S, Tachimori Y, Terado Y, Sakon R, Narita K, Goto M. Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report. J Med Case Rep. 2021;15:237.","journal-title":"J Med Case Rep"},{"key":"1561_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.07.017","volume":"138","author":"P Nenclares","year":"2020","unstructured":"Nenclares P, Ap Dafydd D, Bagwan I, Begg D, Kerawala C, King E, Lingley K, Paleri V, Paterson G, Payne M, Silva P, Steven N, Turnbull N, Yip K, et al. Head and neck mucosal melanoma: the United Kingdom national guidelines. Eur J Cancer. 2020;138:11\u20138.","journal-title":"Eur J Cancer"},{"key":"1561_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10388-004-0021-5","volume":"1","author":"A Itami","year":"2004","unstructured":"Itami A, Makino T, Shimada Y, Imamura M. A case of primary malignant melanoma of the esophagus with long-term survival. Esophagus. 2004;1:135\u20137.","journal-title":"Esophagus"},{"key":"1561_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s10147-004-0473-6","volume":"10","author":"Y Suzuki","year":"2005","unstructured":"Suzuki Y, Aoyama N, Minamide J, Takata K, Ogata T. Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy. Int J Clin Oncol. 2005;10:204\u20137.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"1561_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jjco\/hyl136","volume":"37","author":"Y Ueda","year":"2007","unstructured":"Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, et al. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol. 2007;37(2):140\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"1561_CR13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/JTO.0b013e3181a8ca9f","volume":"4","author":"V Gupta","year":"2009","unstructured":"Gupta V, Kochhar R, Sinha SK, Das A. Primary malignant melanoma of the esophagus: long-term survival after radical resection. J Thorac Oncol. 2009;4:1180\u20132.","journal-title":"J Thorac Oncol"},{"key":"1561_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1759-7714.12063","volume":"4","author":"L Zhang","year":"2013","unstructured":"Zhang L, Ma W, Li Y. Huge primary malignant melanoma of the esophagus: a case report and literature review. Thorac Cancer. 2013;4:479\u201383.","journal-title":"Thorac Cancer"},{"key":"1561_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jss.2020.11.048","volume":"260","author":"AR Kahl","year":"2021","unstructured":"Kahl AR, Gao X, Chioreso C, Goffredo P, Hassan I, Charlton ME, et al. Presentation, management, and prognosis of primary gastrointestinal melanoma: a population-based study. J Surg Res. 2021;260:46\u201355.","journal-title":"J Surg Res"},{"key":"1561_CR16","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s10147-020-01759-x","volume":"25","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Cong C, Su C, Sun Y, Xing L. Epidemiology and survival outcomes of primary gastrointestinal melanoma: a SEER-based population study. Int J Clin Oncol. 2020;25:1951\u20139.","journal-title":"Int J Clin Oncol"},{"key":"1561_CR17","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s10147-020-01618-9","volume":"25","author":"M Nomura","year":"2020","unstructured":"Nomura M, Oze I, Masuishi T, Yokota T, Satake H, Iwasawa S, et al. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. Int J Clin Oncol. 2020;25:972\u20137.","journal-title":"Int J Clin Oncol"},{"key":"1561_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D'Angelo","year":"2017","unstructured":"D\u2019Angelo SP, Larkin J, Sosman JA, Lebb\u00e9 C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35:226\u201335.","journal-title":"J Clin Oncol"},{"key":"1561_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"1561_CR20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"1561_CR21","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"1561_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol"},{"key":"1561_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, CheckMate 648 Trial Investigators, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449\u201362.","journal-title":"N Engl J Med"},{"key":"1561_CR24","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1561_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773\u20139.","journal-title":"J Clin Oncol"},{"key":"1561_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"1561_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"1561_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, CheckMate 577 Investigators, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med"},{"key":"1561_CR29","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102\u201314.","journal-title":"N Engl J Med"},{"key":"1561_CR30","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, CheckMate 238 Collaborators, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"1561_CR31","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465\u201377.","journal-title":"Lancet Oncol"},{"key":"1561_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00280-017-3444-0","volume":"80","author":"M Nomura","year":"2017","unstructured":"Nomura M, Otsuka A, Kondo T, Nagai H, Nonomura Y, Kaku Y, et al. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. Cancer Chemother Pharmacol. 2017;80:999\u20131004.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-022-01561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-022-01561-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-022-01561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T21:06:20Z","timestamp":1667595980000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-022-01561-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1186\/s40792-022-01561-z","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}